Clinical Complete Response after Chemotherapy and Palliative Surgery for Unresectable Gastric Cancer

Abstract

Gastric cancer incidence is high in several countries, and management of advanced gastric cancer remains a challenge. Chemotherapy for unresectable gastric cancers is still evolving, and achieving a complete cure is difficult. Although a clinical complete response to chemotherapy has been reported in patients with unresectable gastric cancer, the chemotherapy duration for these patients is unclear. Here, we report the case of a 71-year-old man who presented with abdominal discomfort. Upper endoscopy revealed advanced gastric cancer on the upper gastric body. Histopathological examination revealed a poorly differentiated adenocarcinoma. Computed tomography revealed regional lymph node and multiple bilobar hepatic metastases. Radical surgery was not possible; therefore, palliative resection of the primary lesion was planned for symptomatic improvement. Tegafur, 5-chloro-2,4-dihydropyrimidine, and potassium oxonate were administered prior to surgery, and proximal gastrectomy was performed. Tegafur, 5-chloro-2,4-dihydropyrimidine, and potassium oxonate administration was reinitiated after surgery. A clinical complete response was achieved in the 8th postoperative month, with no hepatic metastases noted on radio imaging. Computed tomography performed in the 1st postoperative year revealed ascites; however, the cytological examination findings were negative. The initial chemotherapy was discontinued, and paclitaxel administration was commenced. Computed tomography performed annually thereafter demonstrated no recurrence, and paclitaxel was discontinued in the 9th postoperative

Long non‑coding RNA B3GALT5‑AS1 contributes to the progression of gastric cancer via interacting with CSNK2A1

“…Data suggests that gastric cancer ranks second in terms of incidence among all malignancies in China ( 26 , 27 ). Gastric cancer has long been considered to be a difficult challenge to treat clinically ( 28 ). Therapeutic interventions in patients with gastric cancer typically involve alterations in diet, psychological support and changes in daily life habits to optimize the therapeutic effects and improve the quality of life ( 29 ).…”

Long-term survival of HER2 positive gastric cancer patient with multiple liver metastases who obtained pathological complete response after systemic chemotherapy: A case report

“…With the recent progress in the development of anti-cancer drug treatments including molecularly targeted drugs, the number of cases in which even stage IV gastric cancer can be resected without any residue is increasing due to better therapeutic effect. Furthermore, gastric cancer with liver metastasis has a good prognosis when conversion surgery was performed [7] , [8] , [9] , [10] , [11] , [12] .…”